BLIS Tech Announces New Distribution Agreement
20 April, 2007
For Immediate release
BLIS Technologies Ltd Announces New Distribution Agreement.
BLIS Technologies Ltd (NZX: BLT), developer and manufacturer of BLIS K12, an advanced oral probiotic for the prevention of upper respiratory infection and the treatment of chronic bad breath, announced that it has signed a significant distribution and marketing agreement with leading pharmacy distributor Pharmabroker Sales Ltd that will maximize the strong growth and potential of the BLIS’s advanced probiotics.
“We have had a standard distribution arrangement with Pharmabroker, since January 2002” Dr Barry Richardson, BLIS CEO, said today, “but we wanted to further leverage their sales and marketing expertise in New Zealand by expanding the distribution agreement into a more expansive sales and marketing agreement”
The revised deal will see Pharmabroker effectively take over the sales and marketing of all the BLIS products in New Zealand.
“We are a Biotech company with expertise in product and applications development,” Richardson said, “ while Pharmabroker, led by managing director, Jim Davis, is a very effective marketing company, which has a proven record of building retail brands in pharmacies throughout New Zealand.“ Richardson continues, “Jim Davis also understands his customers in ways that would take us years to achieve.”
Dr Richardson has indicated that this revised agreement is part of a broader strategic plan for BLIS Technologies Ltd. By improving retail sales through this distribution and marketing agreement with Pharmabroker Sales Ltd, the company expects to free up resources so it can focus on international segments and building longer term relationships with multi-national corporations. BLIS Technologies Ltd has recently entered into research and development contract with nutrition giant, Nestle.
About Pharmabroker Sales (1986) Ltd
Pharmabroker is a privately held Auckland based company that represents a number of well known local and international brands in New Zealand including Colgate Oral Care, Grans Remedy, Eye-q, Zyrtec, Buccaline and No Jet Lag. Pharmabroker provides New Zealand coverage of retail pharmacy, Health food and medical channels.
About BLIS Technologies Ltd
BLIS Technologies Limited became listed on the New Zealand Stock Exchange in July 2001 and was formed to commercialise BLIS (bacteriocin-like inhibitory substances), hence the company’s name, BLIS Technologies Ltd. The company has acquired the rights to the collection of an extensive range of BLIS producing organisms and is developing new products for use in the control of undesirable bacterial infections which includes dental caries control, the prevention and treatment of ear and throat infections, and skin infections.